Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | QPCT | Q16769 | 1/20 | 0.58 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.57 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9663692 | 0.94 | CYP19A1 (0.80) | CYP19A1KMT2ATBXAS1MAOAMAOB | |
| SCHEMBL9663626 | 0.91 | CYP19A1 (1.00) | CYP19A1KMT2ATBXAS1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL9663915 | 0.90 | CYP19A1 (0.97) | CYP19A1KMT2ATBXAS1MAOAMAOB | |
| SCHEMBL5659339 | 0.82 | KCNJ1 (0.59) | CYP19A1KMT2AMAOAKCNJ1 | |
| SCHEMBL78081 | 0.82 | CYP19A1 (1.00) | CYP19A1KMT2ATBXAS1QPCT | |
| SCHEMBL2749846 | 0.81 | CYP19A1 (0.57) | CYP19A1KMT2ATBXAS1 | |
| SCHEMBL5189230 | 0.81 | QPCT (0.69) | CYP19A1KMT2AMAOAMAOBQPCT | |
| SCHEMBL6642525 | 0.81 | QPCT (0.64) | CYP19A1KMT2ATBXAS1QPCT | |
| SCHEMBL12045347 | 0.80 | HMOX1 (0.84) | CYP19A1KMT2ATBXAS1HMOX1 | |
| SCHEMBL19925993 | 0.80 | NOS1 (0.65) | CYP19A1KMT2AQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-4006243-A | FUNGICIDE, BACTERICIDE, YEAST | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | CYP19A1 86/4885KMT2A 391/4885TBXAS1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.